menu
    • menu
    [{"orgOrder":0,"company":"Federal University of Minas Gerais","sponsor":"Baxter Healthcare Corporation | Medtronic plc","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"BRAZIL","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Propofol","moa":"GABA-A receptor; anion channel","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"Federal University of Minas Gerais","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Federal University of Minas Gerais \/ Baxter Healthcare Corporation | Medtronic plc","highestDevelopmentStatusID":"11","companyTruncated":"Federal University of Minas Gerais \/ Baxter Healthcare Corporation | Medtronic plc"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Fluvastatin Sodium","moa":"HMG-CoA reductase","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Getz Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"PAKISTAN","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"Getz Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Getz Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Getz Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Medical Corps, Israel Defense Force","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"ISRAEL","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Scopolamine","moa":"Muscarinic acetylcholine receptor M1","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"Medical Corps, Israel Defense Force","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical Corps, Israel Defense Force \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Medical Corps, Israel Defense Force \/ Undisclosed"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Healthway Pharmacy | Michigan Public Health Departments | National Institute of Environmental Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Orlistat","moa":"Pancreatic lipase | Gastric lipase","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gabrail Cancer Center Research \/ Healthway Pharmacy | Michigan Public Health Departments | National Institute of Environmental Health Sciences","highestDevelopmentStatusID":"11","companyTruncated":"Gabrail Cancer Center Research \/ Healthway Pharmacy | Michigan Public Health Departments | National Institute of Environmental Health Sciences"},{"orgOrder":0,"company":"University of Florence","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"ITALY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sugammadex Sodium","moa":"Rocuronium","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"University of Florence","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Florence \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"University of Florence \/ Merck & Co"},{"orgOrder":0,"company":"American Regent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Tralement","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"American Regent \/ Undisclosed"},{"orgOrder":0,"company":"American Regent","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Tralement","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"American Regent \/ Undisclosed"},{"orgOrder":0,"company":"Heart Health Research Center","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Xuezhikang","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase IV","graph3":"Heart Health Research Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Heart Health Research Center \/ AstraZeneca","highestDevelopmentStatusID":"11","companyTruncated":"Heart Health Research Center \/ AstraZeneca"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            American Regent

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            American Regent

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tralement

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tralement vs. Fixed-dose Trace Element Combination Product in Patients >3 to 17 Years of Age Requiring Long-te...

                            Details : Tralement is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Manganese Poisoning.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 10, 2023

                            Lead Product(s) : Tralement

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            American Regent

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            American Regent

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tralement

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tralement Versus a Fixed-dose Trace Element Combination Product to Evaluate Manganese Safety

                            Details : Tralement is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Manganese Poisoning.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 22, 2022

                            Lead Product(s) : Tralement

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Heart Health Research Center

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Heart Health Research Center

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Xuezhikang

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase IV

                            Sponsor : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabe...

                            Details : Xuezhikang is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Lipid Metabolism Disorders.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            February 14, 2022

                            Lead Product(s) : Xuezhikang

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase IV

                            Sponsor : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Getz Pharma

                            Pakistan arrow
                            OTS 2025
                            Not Confirmed

                            Getz Pharma

                            Pakistan arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Research on Human Insulin rDNA Safety and Efficacy in Patients With Type 2 Diabetes Mellitus

                            Details : Insulin is a Hormone drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Drug-Related Side Effects and Adverse Reactions.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            December 17, 2021

                            Lead Product(s) : Insulin

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Gabrail Cancer Center Research

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Gabrail Cancer Center Research

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Orlistat

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase IV

                            Sponsor : Healthway Pharmacy | Michigan Public Health Departments | National Institute of Environmental Health Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Weight Loss Aid in an Exposed Population

                            Details : Orlistat is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Polybrominated Biphenyl Poisoning.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 11, 2018

                            Lead Product(s) : Orlistat

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase IV

                            Sponsor : Healthway Pharmacy | Michigan Public Health Departments | National Institute of Environmental Health Sciences

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Medical Corps, Israel Defense Force

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Medical Corps, Israel Defense Force

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Scopolamine

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Motion Sickness Medications and Vestibular Time Constant

                            Details : Scopolamine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Drug-Related Side Effects and Adverse Reactions.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 01, 2017

                            Lead Product(s) : Scopolamine

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            University of Florence

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            University of Florence

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sugammadex Sodium

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase IV

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Recovery of Muscle Function After Deep Neuromuscular Block by Means of Diaphragm Ultrasonography

                            Details : Sugammadex is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Delayed Emergence from Anesthesia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 04, 2016

                            Lead Product(s) : Sugammadex Sodium

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase IV

                            Sponsor : Merck & Co

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Federal University of Minas Gerais

                            Country arrow
                            OTS 2025
                            Not Confirmed

                            Federal University of Minas Gerais

                            Country arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Propofol

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase IV

                            Sponsor : Baxter Healthcare Corporation | Medtronic plc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Recovery Profile Comparison Between Remifentanil-propofol or Desflurane Anesthesia Monitored With Bispectral I...

                            Details : Propofol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Delayed Emergence from Anesthesia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 16, 2015

                            Lead Product(s) : Propofol

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase IV

                            Sponsor : Baxter Healthcare Corporation | Medtronic plc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            OTS 2025
                            Not Confirmed

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluvastatin Sodium

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With P...

                            Details : Fluvastatin Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Lipid Metabolism Disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 12, 2012

                            Lead Product(s) : Fluvastatin Sodium

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth